Eli Lilly and Company (NYSE:LLY) Stock Price Down 2.1% – Here’s What Happened

Eli Lilly and Company (NYSE:LLY)’s share price dropped 2.1% on Thursday . The stock traded as low as $965.60 and last traded at $982.85. Approximately 3,760,008 shares changed hands during mid-day trading, an increase of 14% from the average daily volume of 3,306,408 shares. The stock had previously closed at $1,003.57.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly launched “Lilly Employer Connect,” a direct-to-employer platform designed to broaden employer coverage of obesity drugs (including Zepbound/tirzepatide), with flexible benefit designs and a $449 single?patient KwikPen option to lower out-of-pocket costs and speed adoption. This can increase uptake and reduce payer friction for high-margin obesity medicines. PR Newswire: Employer Connect launch
• Positive Sentiment: Multiple outlets report Lilly is actively pitching employers to cover GLP?1/dual?agonist obesity treatments — a distribution push that could materially expand the patient base and underpin continued sales growth for Mounjaro/Zepbound. CNBC: Employer coverage program
• Positive Sentiment: Pipeline progress: Lilly completed/updated the TRANSCEND?T2D?1 retatrutide Phase 3 program and advanced an abemaciclib combination in prostate cancer (early?stage data), both reinforcing long?term growth levers beyond weight?loss drugs. Positive trial news supports upside to future revenue and de?risking of promising assets. TipRanks: TRANSCEND?T2D?1 update
• Positive Sentiment: Regulatory tailwind in immunology: the EMA issued a positive opinion on Olumiant for alopecia, which could broaden Lilly’s immunology footprint and diversify revenue streams outside metabolic drugs. Yahoo Finance: EMA Olumiant opinion
• Neutral Sentiment: Lilly continues M&A/partnering activity (Ventyx Biosciences merger approval), which adds R&D assets but is incremental to the core GLP?1/peptide franchise; monitor integration and milestones. TipRanks: Ventyx merger approval
• Negative Sentiment: Investor concerns on pricing, competition and a recent pullback: analysts and commentary note a month?long decline amid fears of pricing pressure, insurer/employer cost controls, and rival weight?loss entrants — factors that can compress near?term growth expectations and valuations. Zacks: pricing fears and competition

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Jefferies Financial Group upped their price objective on Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Berenberg Bank upped their price target on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research note on Thursday, February 19th. HSBC reiterated a “hold” rating and set a $1,070.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Daiwa Securities Group boosted their price objective on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Finally, TD Cowen increased their target price on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,229.59.

Eli Lilly and Company Price Performance

The company has a market capitalization of $927.18 billion, a PE ratio of 42.83, a price-to-earnings-growth ratio of 1.17 and a beta of 0.40. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The stock’s 50 day simple moving average is $1,049.25 and its 200-day simple moving average is $936.91.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the previous year, the business posted $5.32 earnings per share. The business’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is 30.15%.

Institutional Investors Weigh In On Eli Lilly and Company

Several large investors have recently bought and sold shares of the stock. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $39,000. Mengis Capital Management Inc. grew its holdings in Eli Lilly and Company by 5.3% during the 4th quarter. Mengis Capital Management Inc. now owns 9,874 shares of the company’s stock worth $10,612,000 after acquiring an additional 500 shares in the last quarter. Storen Legacy Partners LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $11,333,000. Worthington Financial Partners LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $843,000. Finally, Bayban acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $170,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.